Basal cell carcinoma pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(17 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Basal cell carcinoma}}
{{Basal cell carcinoma}}
{{CMG}};{{AE}}{{SM}}
{{CMG}};{{AE}}{{M.N}}
 
==Overview==
==Overview==
Basal cell carcinoma is one of the most common [[skin cancers]]. It is commonly known as [[rodent ulcer]] due to its distinct [[Morphology (biology)|morphology]] characterized by pearly pink [[nodules]] with [[telangiectasias]], rolled borders, and central crusting with or without an [[Ulceration|ulcerating]] [[lesion]]. The most common [[Causes|cause]] for the [[development]] of the basal cell carcinoma involves [[radiation exposure]] and [[mutations]] that involve many [[genes]] including sonic [[Hedgehog (cell signaling)|hedgehog]] [[gene]], [[PTCH1]] [[gene]], and other [[Gain-of-function mutation|gain-of-function mutations]] which further depend on the subtypes such as [[nodular]], [[superficial]], Infundibulocystic, fibroepithelial, morpheaform, infiltrative, micronodular, and basosquamous basal cell carcinomas.
Basal cell carcinoma is one of the most common [[skin cancers]]. It is commonly known as [[rodent ulcer]] due to its distinct [[Morphology (biology)|morphology]] characterized by pearly pink [[nodules]] with [[telangiectasias]], rolled borders, and central crusting with or without an [[Ulceration|ulcerating]] [[lesion]]. The majority common [[Causes|cause]] for the [[development]] of the basal cell carcinoma involves [[radiation exposure]] and [[mutations]] that involve many [[genes]] including sonic [[Hedgehog (cell signaling)|hedgehog]] [[gene]], [[PTCH1]] [[gene]], and other [[Gain-of-function mutation|gain-of-function mutations]] which further depend on the subtypes such as [[nodular]], [[superficial]], Infundibulocystic, [[fibroepithelial]], morpheaform, infiltrative, micronodular, and basosquamous basal cell carcinomas.


==Pathophysiology==
==Pathophysiology==
===Pathogenesis===
The exact pathogenesis of basal cell carcinoma is not completely understood
===Genetics===
===Genetics===
*A [[number]] of aberrations involving the [[sonic hedgehog]] [[signaling pathway]](SHH) are noted<ref name="pmid24587976">{{cite journal |vauthors=Mohan SV, Chang AL |title=Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations |journal=Curr Dermatol Rep |volume=3 |issue= |pages=40–45 |date=2014 |pmid=24587976 |pmc=3931971 |doi=10.1007/s13671-014-0069-y |url=}}</ref><ref name="pmid29165358">{{cite journal |vauthors=Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli MC |title=Understanding the Molecular Genetics of Basal Cell Carcinoma |journal=Int J Mol Sci |volume=18 |issue=11 |pages= |date=November 2017 |pmid=29165358 |pmc=5713451 |doi=10.3390/ijms18112485 |url=}}</ref><ref name="pmid30405815">{{cite journal |vauthors=Yunoki T, Tabuchi Y, Hirano T, Miwa S, Imura J, Hayashi A |title=Gene networks in basal cell carcinoma of the eyelid, analyzed using gene expression profiling |journal=Oncol Lett |volume=16 |issue=5 |pages=6729–6734 |date=November 2018 |pmid=30405815 |pmc=6202553 |doi=10.3892/ol.2018.9484 |url=}}</ref>
The development of basal cell carcinoma is the result of multiple genetic mutations such as sonic hedgehog pathway mutations, and PTCH1 gene mutations
*This pathway is [[vital]] for the [[Regulation of gene expression|regulation]] of [[cell growth]], and [[differentiation]] and loss of [[inhibition]] of this pathway is associated with [[development]] of basal cell cancer
*A [[number]] of aberrations involving the [[sonic hedgehog]] [[signaling pathway]](SHH) are noted.<ref name="pmid24587976">{{cite journal |vauthors=Mohan SV, Chang AL |title=Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations |journal=Curr Dermatol Rep |volume=3 |issue= |pages=40–45 |date=2014 |pmid=24587976 |pmc=3931971 |doi=10.1007/s13671-014-0069-y |url=}}</ref><ref name="pmid29165358">{{cite journal |vauthors=Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli MC |title=Understanding the Molecular Genetics of Basal Cell Carcinoma |journal=Int J Mol Sci |volume=18 |issue=11 |pages= |date=November 2017 |pmid=29165358 |pmc=5713451 |doi=10.3390/ijms18112485 |url=}}</ref><ref name="pmid30405815">{{cite journal |vauthors=Yunoki T, Tabuchi Y, Hirano T, Miwa S, Imura J, Hayashi A |title=Gene networks in basal cell carcinoma of the eyelid, analyzed using gene expression profiling |journal=Oncol Lett |volume=16 |issue=5 |pages=6729–6734 |date=November 2018 |pmid=30405815 |pmc=6202553 |doi=10.3892/ol.2018.9484 |url=}}</ref><ref name="pmid26029015">{{cite journal |vauthors=Marzuka AG, Book SE |title=Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management |journal=Yale J Biol Med |volume=88 |issue=2 |pages=167–79 |date=June 2015 |pmid=26029015 |pmc=4445438 |doi= |url=}}</ref>
*The majority of [[mutations]] in sporadic basal cell carcinoma and [[basal cell nevus syndrome]](BCNS) [[patients]] occur in [[PTCH1]] [[gene]], a [[protein]] that inhibits smoothened [[gene]](SMO)
*This pathway is [[vital]] for the [[Regulation of gene expression|regulation]] of [[cell growth]], and [[differentiation]] and loss of [[inhibition]] of this pathway is associated with [[development]] of basal cell cancer.
*The [[second]] most common [[mutation]] in sporadic basal cell carcinoma and [[basal cell nevus syndrome]](BCNS) [[patients]] are [[Gain-of-function mutation|gain-of-function]] [[mutations]] of the smoothened [[gene]](SMO)
*The majority of [[mutations]] in sporadic basal cell carcinoma and [[basal cell nevus syndrome]](BCNS) [[patients]] occur in [[PTCH1]] [[gene]], a [[protein]] that inhibits smoothened [[gene]] (SMO).
*Loss of [[PTCH1]] results in the failure of Smoothened [[inhibition]], subsequently leading to increases in [[GLI1]] levels, changes in [[transcription]], and subsequent [[tumorigenesis]]
*The [[second]] most common [[mutation]] in sporadic basal cell carcinoma and [[basal cell nevus syndrome]](BCNS) [[patients]] are [[Gain-of-function mutation|gain-of-function]] [[mutations]] of the smoothened [[gene]] (SMO).
*Loss of [[PTCH1]] results in the failure of Smoothened [[inhibition]], subsequently leading to increases in [[GLI1]] levels, changes in [[transcription]], and subsequent [[tumorigenesis]].
*[[Gain-of-function mutation|Gain-of-function]] smoothened(SMO) [[mutations]] also leads to increased [[GLI1]] levels and [[tumorigenesis]]
*[[Gain-of-function mutation|Gain-of-function]] smoothened(SMO) [[mutations]] also leads to increased [[GLI1]] levels and [[tumorigenesis]]
{{Family tree/start}}  
{{Family tree/start}}  
Line 29: Line 31:
{{Family tree | | | | E01 | | | |E01= Tumorigenesis}}
{{Family tree | | | | E01 | | | |E01= Tumorigenesis}}
{{Family tree/end}}
{{Family tree/end}}
[[File:Soinic hedgehog pathway signalling.jpg|thumb|500px|none|Sonic hedgehog signaling pathway. SHH ligand binds to and inhibits the PTCH transmembrane protein. The inhibition of PTCH relieves suppression of / (Smoothened), which then activates the GLI transcription factors. The GLI proteins translocate from the cytoplasm to the nucleus, where they drive gene transcription. (Courtesy of Alexander G. Marzuka, MD),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445438/]]
Other Genetic Changes:
*Point mutations in the TP53 gene, the tumor supressor gene are the second most common genetic alteration noticed in BCCs
*Some mutations in the CDKN2A locus and in ras gene family (H-ras, K-ras, and N-ras) are also identified in a smaller proportion of sporadic BCCs


===Enviromental Exposure===
===Enviromental Exposure===
*Basal cell carcinomas develop in the [[basal cell layer]] of the [[skin]]
*Basal cell carcinomas develop in the [[basal cell layer]] of the [[skin]].<ref name="pmid28954101">{{cite journal |vauthors=Montagna E, Lopes OS |title=Molecular basis of basal cell carcinoma |journal=An Bras Dermatol |volume=92 |issue=4 |pages=517–520 |date=2017 |pmid=28954101 |pmc=5595599 |doi=10.1590/abd1806-4841.20176544 |url=}}</ref>
*Cumulative [[DNA damage]] caused by [[chronic]] [[sunlight]] exposure results in [[DNA mutations]] that predispose to the [[development]] of basal cell carcinoma
*Cumulative [[DNA damage]] caused by [[chronic]] [[sunlight]] exposure results in [[DNA mutations]] that predispose to the [[development]] of basal cell carcinoma.
*While [[DNA repair]] eliminates most [[Ultraviolet|UV-]]<nowiki/>induced damage, not all cross-links are excised, which eventually results in [[mutation]]s
*While [[DNA repair]] eliminates most [[Ultraviolet|UV-]]<nowiki/>induced damage, not all cross-links are excised, which eventually results in [[mutation]]s.
*Apart from the [[mutagenesis]], [[sunlight]] [[depresses]] the local [[immune system]], possibly decreasing [[immune]] surveillance for [[new]] [[Tumor cell|tumor cells]]
*Apart from the [[mutagenesis]], [[sunlight]] [[depresses]] the local [[immune system]], possibly decreasing [[immune]] surveillance for [[new]] [[Tumor cell|tumor cells]].


===Pathology===
===Gross and microscopic pathology===
Basal cell carcinoma [[pathological]] features mainly depend upon the subtype. The following table summarizes them:<ref name="CameronLee2019">{{cite journal|last1=Cameron|first1=Michael C.|last2=Lee|first2=Erica|last3=Hibler|first3=Brian P.|last4=Barker|first4=Christopher A.|last5=Mori|first5=Shoko|last6=Cordova|first6=Miguel|last7=Nehal|first7=Kishwer S.|last8=Rossi|first8=Anthony M.|title=Basal cell carcinoma|journal=Journal of the American Academy of Dermatology|volume=80|issue=2|year=2019|pages=303–317|issn=01909622|doi=10.1016/j.jaad.2018.03.060}}</ref><ref name="pmid25134314">{{cite journal |vauthors=Sehgal VN, Chatterjee K, Pandhi D, Khurana A |title=Basal cell carcinoma: pathophysiology |journal=Skinmed |volume=12 |issue=3 |pages=176–81 |date=2014 |pmid=25134314 |doi= |url=}}</ref>
*On gross and microscopic histopathological analysis the characteristic findings of basal cell carcinoma are described as below:
*Basal cell carcinoma [[pathological]] features mainly depend upon the subtype. The following table summarizes them:<ref name="CameronLee2019">{{cite journal|last1=Cameron|first1=Michael C.|last2=Lee|first2=Erica|last3=Hibler|first3=Brian P.|last4=Barker|first4=Christopher A.|last5=Mori|first5=Shoko|last6=Cordova|first6=Miguel|last7=Nehal|first7=Kishwer S.|last8=Rossi|first8=Anthony M.|title=Basal cell carcinoma|journal=Journal of the American Academy of Dermatology|volume=80|issue=2|year=2019|pages=303–317|issn=01909622|doi=10.1016/j.jaad.2018.03.060}}</ref><ref name="pmid25134314">{{cite journal |vauthors=Sehgal VN, Chatterjee K, Pandhi D, Khurana A |title=Basal cell carcinoma: pathophysiology |journal=Skinmed |volume=12 |issue=3 |pages=176–81 |date=2014 |pmid=25134314 |doi= |url=}}</ref>


{| class="wikitable"
{| class="wikitable"
|-
|-
! rowspan="2" | Subtypes of BCC
| rowspan="2" align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Subtypes of BCC'''}}
! colspan="2" | Gross features
| colspan="2" align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Gross features'''}}
! colspan="2" | Microscopic features
| colspan="2" align="center" style="background: #4479BA;" | {{fontcolor|#FFF|''' Microscopic features'''}}
|-
|-
!Findings
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Findings'''}}
!Images
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Images'''}}
!Findings
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Findings'''}}
!Images
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Images'''}}
|-
|-
| [[Nodular]]
| [[Nodular]]
Line 159: Line 166:
{{Reflist|2}}
{{Reflist|2}}


[[Category:Disease]]
[[Category:Dermatology]]
[[Category:Types of cancer]]
[[Category:Pathology]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Surgery]]
[[Category:Surgery]]

Latest revision as of 18:25, 4 April 2019

Basal cell carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Basal Cell Carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT scan

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Basal cell carcinoma pathophysiology On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Basal cell carcinoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Basal cell carcinoma pathophysiology

CDC on Basal cell carcinoma pathophysiology

Basal cell carcinoma pathophysiology in the news

Blogs on Basal cell carcinoma pathophysiology

Directions to Hospitals Treating Basal cell carcinoma

Risk calculators and risk factors for Basal cell carcinoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2]

Overview

Basal cell carcinoma is one of the most common skin cancers. It is commonly known as rodent ulcer due to its distinct morphology characterized by pearly pink nodules with telangiectasias, rolled borders, and central crusting with or without an ulcerating lesion. The majority common cause for the development of the basal cell carcinoma involves radiation exposure and mutations that involve many genes including sonic hedgehog gene, PTCH1 gene, and other gain-of-function mutations which further depend on the subtypes such as nodular, superficial, Infundibulocystic, fibroepithelial, morpheaform, infiltrative, micronodular, and basosquamous basal cell carcinomas.

Pathophysiology

Pathogenesis

The exact pathogenesis of basal cell carcinoma is not completely understood

Genetics

The development of basal cell carcinoma is the result of multiple genetic mutations such as sonic hedgehog pathway mutations, and PTCH1 gene mutations

 
 
 
Loss of PTCH1
 
 
 
Gain of function SMO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lack of SMO inhibition
 
 
 
Activation of
SMO-GLI signaling
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
↑GLI1 levels
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Changes in transcription
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tumorigenesis
 
 
 
Sonic hedgehog signaling pathway. SHH ligand binds to and inhibits the PTCH transmembrane protein. The inhibition of PTCH relieves suppression of / (Smoothened), which then activates the GLI transcription factors. The GLI proteins translocate from the cytoplasm to the nucleus, where they drive gene transcription. (Courtesy of Alexander G. Marzuka, MD),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445438/

Other Genetic Changes:

  • Point mutations in the TP53 gene, the tumor supressor gene are the second most common genetic alteration noticed in BCCs
  • Some mutations in the CDKN2A locus and in ras gene family (H-ras, K-ras, and N-ras) are also identified in a smaller proportion of sporadic BCCs

Enviromental Exposure

Gross and microscopic pathology

  • On gross and microscopic histopathological analysis the characteristic findings of basal cell carcinoma are described as below:
  • Basal cell carcinoma pathological features mainly depend upon the subtype. The following table summarizes them:[6][7]
Subtypes of BCC Gross features Microscopic features
Findings Images Findings Images
Nodular
M. Sand, D. Sand, C. Thrandorf, V. Paech, P. Altmeyer, F. G. Bechara [CC BY 2.0 (https://creativecommons.org/licenses/by/2.0)], via Wikimedia Commons
No machine-readable author provided. KGH assumed (based on copyright claims). [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0/)], via Wikimedia Commons,https://upload.wikimedia.org/wikipedia/commons/b/b6/Basal_cell_carcinoma_histopathology_%283%29.jpg
Superficial
Kelly Nelson (Photographer) [Public domain], via Wikimedia Commons,https://upload.wikimedia.org/wikipedia/commons/3/32/Basal_cell_carcinoma%2C_superficial.jpg
machine-readable author provided. KGH assumed (based on copyright claims). [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0/)], via Wikimedia Commons
Infundibulocystic
  • Well-circumscribed pearly papule
  • Most common on the head and neck region
Fibroepithelial
Morpheaform
Dermatology Centre, Salford Royal Hospital, NHS Foundation Trust, Stott Lane, Salford M6 8HD, UK.
Department of Pathology, Columbia University Medical Center, New York, USA
Infiltrative
Kelly Nelson (Photographer) [Public domain], via Wikimedia Commons,https://upload.wikimedia.org/wikipedia/commons/9/9b/Basal_cell_carcinoma_%281%29.jpg,
Micronodular
  • Multiple small aggregates of basaloid cells within the dermis, with subtle peripheral palisading and retraction artifact
Basosquamous

Video

{{#ev:youtube|JnJXrFnvOKs}}

References

  1. ↑ Mohan SV, Chang AL (2014). "Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations". Curr Dermatol Rep. 3: 40–45. doi:10.1007/s13671-014-0069-y. PMC 3931971. PMID 24587976.
  2. ↑ Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli MC (November 2017). "Understanding the Molecular Genetics of Basal Cell Carcinoma". Int J Mol Sci. 18 (11). doi:10.3390/ijms18112485. PMC 5713451. PMID 29165358.
  3. ↑ Yunoki T, Tabuchi Y, Hirano T, Miwa S, Imura J, Hayashi A (November 2018). "Gene networks in basal cell carcinoma of the eyelid, analyzed using gene expression profiling". Oncol Lett. 16 (5): 6729–6734. doi:10.3892/ol.2018.9484. PMC 6202553. PMID 30405815.
  4. ↑ Marzuka AG, Book SE (June 2015). "Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management". Yale J Biol Med. 88 (2): 167–79. PMC 4445438. PMID 26029015.
  5. ↑ Montagna E, Lopes OS (2017). "Molecular basis of basal cell carcinoma". An Bras Dermatol. 92 (4): 517–520. doi:10.1590/abd1806-4841.20176544. PMC 5595599. PMID 28954101.
  6. ↑ Cameron, Michael C.; Lee, Erica; Hibler, Brian P.; Barker, Christopher A.; Mori, Shoko; Cordova, Miguel; Nehal, Kishwer S.; Rossi, Anthony M. (2019). "Basal cell carcinoma". Journal of the American Academy of Dermatology. 80 (2): 303–317. doi:10.1016/j.jaad.2018.03.060. ISSN 0190-9622.
  7. ↑ Sehgal VN, Chatterjee K, Pandhi D, Khurana A (2014). "Basal cell carcinoma: pathophysiology". Skinmed. 12 (3): 176–81. PMID 25134314.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Basal_cell_carcinoma_pathophysiology&oldid=1561376"